Aptose Biosciences (NASDAQ:APTO) Shares Scheduled to Reverse Split on Wednesday, February 26th

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) shares are set to reverse split before the market opens on Wednesday, February 26th. The 1-30 reverse split was announced on Tuesday, February 18th. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, February 25th.

Aptose Biosciences Trading Up 7.6 %

Shares of APTO stock traded up $0.01 during trading hours on Tuesday, hitting $0.19. The company’s stock had a trading volume of 4,882,723 shares, compared to its average volume of 5,252,953. Aptose Biosciences has a twelve month low of $0.13 and a twelve month high of $2.01. The stock has a market cap of $11.65 million, a price-to-earnings ratio of -0.07 and a beta of 0.88. The business has a fifty day moving average of $0.21 and a 200-day moving average of $0.31.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on APTO. StockNews.com began coverage on Aptose Biosciences in a report on Monday. They issued a “hold” rating for the company. HC Wainwright reiterated a “buy” rating and set a $2.00 target price on shares of Aptose Biosciences in a research report on Wednesday, February 12th.

Institutional Trading of Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Bleichroeder LP purchased a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 2,500,000 shares of the biotechnology company’s stock, valued at approximately $563,000. Bleichroeder LP owned about 4.15% of Aptose Biosciences at the end of the most recent quarter. Institutional investors and hedge funds own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.